Bioanalysis validation: case example

Slides:



Advertisements
Similar presentations
Bioavailability Bioavailability means the rate and extent to which the active substance is adsorbed from a pharmaceutical product and become available.
Advertisements

CAP/POCT 2003 Carol Riley-Hunte, RRT Senior Education Specialist Bayer HealthCare.
Anne Sholander, MT(ASCP), International QA/QC Coordinator, SMILE
Interpreting of Patient-Reported Outcomes
Neurological Predictors of Huntington’s Disease
Nursing and Lab partnering to perform
Clinical Trials Approach and the Pediatric Trials Network Danny Benjamin, MD, PhD, MPH Professor, Duke University.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Updates and Lessons Learned from Pediatric Trials Network (PTN) Michael Cohen-Wolkowiez, MD, PhD Assistant Professor Duke University Michael Cohen-Wolkowiez,
Pharmacokinetics and Safety of Metronidazole in Preterm Infants: Validation of Dried Blood Spot Sampling Mario Sampson, PharmD Duke Clinical Research Institute.
Analytical considerations Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Validation of Analytical Methods Used For Bioequivalence.
Alfredo García – Arieta, PhD WHO Workshop on Assessment of Bioequivalence Data, 31 August – 3 September, 2010, Addis Ababa Analytical Considerations.
Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.
ABC of Quality Control A problem based approach RT ERASMUS NHLS / FACULTY OF HEALTH SCIENCES, UNIVERSITY OF STELLENBOSCH 20th July, 2007, Bela Bela.
Analytical considerations
NICHD Perspective on Needs for the Study of Therapeutic Drug Use in Pregnancy Catherine Y Spong, MD PPB, CRMC, NICHD, NIH.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.
The USP Performance Test Dissolution Systems Suitability Studies Walter W. Hauck, Ph.D. USP Consultant Presentation to Advisory Committee for Pharmaceutical.
Endocrinologic & Metabolic Drugs Advisory Committee Meeting
Investigating Out of Specification Results
Trials and Tribulations of Developing a Method for Quantification of Aerosol Chamber Concentration Richard Snell, Dose Concentration Analysis GSK.
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
 Remember Chemistry panel Quality Control:-  In a medical laboratory, it is a statistical process used to monitor and evaluate the analytical process.
Pre- analytic Analytic Post- analytic  S pecimen collection  Specimen transport  Specimen quality  Result accuracy  Clerical.
Result Authorisation – Correct or Not? Julie RYAN FAACB Chair SRAC AACB Healthscope Pathology.
FAQ – Omnitest ® plus August FAQ – Omnitest ® plus 1.Which sort of blood has to be used? 2.What is the hematocrit range? 3.Could the system be used.
A Dipstick Protein and specific Gravity Algorithm Accurately Predicts Pathological Proteinuria Marigel Constantiner, RPh, MS, Ashwini R. Sehgal, MD, Lisa.
FACTORS THAT MAY INFLUENCE CLINICAL LABORATORY RESULTS Dr KB Sedumedi DEPT OF CHEMICAL PATHOLOGY.
Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval  Kanecia Zimmerman,
Quality Assessment.
Quality Assurance Procedure Manuals.
A. Evaluation point Hospitalization (10 or more days)
Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for.
Frequently Asked Questions - FAQ
Unit #6 - Basic Quality Control for the Clinical Laboratory
Introduction Results Aim of the study Methods Conclusion References
Duke Surgery Research Training Fellowship
FDA’s IDE Decisions and Communications
A Comparison of the Systems for the Identification of Postoperative Acute Kidney Injury in Pediatric Cardiac Patients  Daniel J. Lex, MD, Roland Tóth,
Workflow Benefits of Test-specific thresholds on Sysmex CS analysers
Analytical considerations
Volume 54, Issue 2, Pages (August 1998)
Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure  Tao-Sheng Li, MD, PhD, Masayuki Kubo, PhD,
به نام خدا تضمين کيفيت در آزمايشگاه
Using Laboratory Test Results at Hospital Admission to Predict Short-term Survival in Critically Ill Patients With Metastatic or Advanced Cancer  Lee.
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.
John Fanikos, RPh, MBA, Allison E. Burnett, PharmD, Charles E
Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic.
Vahab Fatourechi, M. D. , Frank P. Kennedy, M. D. , Robert A. Rizza, M
Cold blood versus cold crystalloid cardioplegia for repair of ventricular septal defects in pediatric heart surgery: a randomized controlled trial  Massimo.
Jan Havlin, MD, PhD, Karel Matousovic, DSc, Otto Schück, MD, DSc 
Is chemiluminescent immunoassay an appropriate substitution for radioimmunoassay in monitoring estradiol levels?  Avner Hershlag, M.D., Michael Zinger,
Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia  Andrew G. Bostom,
Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure  Tao-Sheng Li, MD, PhD, Masayuki Kubo, PhD,
Quality Control Lecture 3
Opening an IND: Investigator Perspective
Development Plans: Study Design and Dose Selection
G. Michael Felker et al. JCHF 2014;2:
Routine Laboratory Testing Every 4 Versus Every 6 Weeks for Patients on Maintenance Hemodialysis: A Quality Improvement Project  Samuel A. Silver, Abdullah.
Quiz Page July 2012 American Journal of Kidney Diseases
Serum Vitamin C (mg/dl) by Salad Intake
Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States  George A. Kaysen, MD, PhD, Kirsten.
Volume 60, Issue 6, Pages (December 2001)
Drug Therapy in Pediatric Patients
Chi-Yuan Hsu, M.D., M.Sc., Glenn M. Chertow, Gary C. Curhan 
Pediatric in-center hemodialysis patients
Percentage of all inborn infants ≥34 weeks’ gestation who (A) received ampicillin or (B) had CRP measured during the first 3 days surrounding the practice.
Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial  Michael N. D'Ambra, MD, Cary W. Akins,
Presentation transcript:

Bioanalysis validation: case example Michael Cohen-Wolkowiez, MD PhD Pediatric Trials Network Professor of Pediatrics, Duke University

Background Meropenem study 188 infants PK and safety NIH funded ($~5M) Registration to FDA for labeling consideration Bioanalysis information Blood volume: appropriate FDA standards?

Meropenem study: high level results CL = 0.122 X (0.5/SCR)0.267 X (PMA/32.7)1.46 SCR: serum creatinine; PMA: postmenstrual age

FDA observations and recommendations Anticoagulant used for QC and calibration standard preparation different from patient samples Stability samples used for freeze/thaw and bench top stability not compared against freshly prepared references Failure to use appropriate QC sample concentrations Failure to reject analytical runs when low concentration QCs were outside 15% of their nominal value Recommendation: clinical trial data unacceptable

Action and results Lab 2 Lab 1 Lab 1 Lab 2 N 188 171   Lab 1 Lab 2 N 188 171 Gestational age (weeks) 28 (23-40) Postnatal age (days) 22 (1-92) 23 (1-92) Serum creatinine (mg/dL) 0.5 (0.1-1.9) 0.4 (0.1-1.9) Albumin (g/dL) 2.3 (1.0-4.5) Lab 1 Lab 2

Tips: big ticket items FDA guidance for bioanalysis Blood volume Anticoagulant Concentration range Lower limit of quantification (LLOQ)